Home

Vivo Capital Fund VIII, L.P.

CIK 1618788 · last filed 2022-08-16

Vivo Capital Fund VIII, L.P. is a corporate insider who has filed 8 SEC Form 4 insider transactions across 5 companies since 2017. The most recent filing, for TERN, was dated Apr 3, 2024. Across all open-market trades the lifetime net is +$104.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $208.8M across reported positions. The firm reports its address in Palo Alto, CA. 31 SEC filings were submitted jointly with Vivo Capital Surplus Fund VIII, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$208.84M

Companies

5

Total Filings

8

Lifetime Open-Market Net

$104.47M

Filer Profile

Reported Address
505 HAMILTON AVENUE, SUITE 200
PALO ALTO, CA 94301
Phone
(650) 688-0818
Related Filers
Vivo Capital Surplus Fund VIII, L.P. — 31 joint filings, latest 2024-04-03
Vivo Capital VIII, LLC — 28 joint filings, latest 2024-04-03
Vivo Opportunity, LLC — 15 joint filings, latest 2024-04-03
Vivo Opportunity Fund, L.P. — 9 joint filings, latest 2021-02-09
Vivo Opportunity Fund Holdings, L.P. — 6 joint filings, latest 2024-04-03
Vivo Panda, LLC — 4 joint filings, latest 2023-11-22
VIVO VENTURES VII, LLC — same reported address
Vivo Ventures Fund V, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Terns Pharmaceuticals, Inc. (TERN) Delisted 10%+ Owner 281,223 $52.95 $14.89M $75.28M 2 2022-08-16
IPI Legacy Liquidation Co (IMPL) Delisted 10%+ Owner 1,625,022 $0.24 $391.8K $25.88M 1 2021-04-29
CRNX 10%+ Owner 2,458,445 $84.95 $208.84M -$12.68M 1 2020-04-07
VYNE Therapeutics Inc. (MNLO) Delisted 10%+ Owner 3,524,541 — — $15.00M 1 2018-01-29
Timber Pharmaceuticals, Inc. (BPMX) Delisted 10%+ Owner 1,174,695 — — $1.00M 1 2017-05-01

Recent Filings

8 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-04-03 Terns Pharmaceuticals, Inc. (TERN) Delisted Notice (144) −39,416 -$236.5K EDGAR
2024-04-01 Terns Pharmaceuticals, Inc. (TERN) Delisted Notice (144) −63,956 -$454.7K EDGAR
2022-08-16 Terns Pharmaceuticals, Inc. (TERN) Delisted Buy (P) +13,121,195 $34.90M EDGAR
2021-04-29 IPI Legacy Liquidation Co (IMPL) Delisted Mixed +8,654,367 $29.98M EDGAR
2021-02-09 Terns Pharmaceuticals, Inc. (TERN) Delisted Mixed +13,375,665 $40.38M EDGAR
2020-04-07 CRNX Sell (S) −918,345 -$12.68M EDGAR
2018-01-29 VYNE Therapeutics Inc. (MNLO) Delisted Mixed +12,033,708 $15.00M EDGAR
2017-05-01 Timber Pharmaceuticals, Inc. (BPMX) Delisted Buy (P) +1,282,052 $1.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.